Published in Medical Letter on the CDC and FDA, October 19th, 2003
Approximately $3 million will be distributed to the institutions over the next 3 years to examine such issues as the bacteria's genetic characteristics, characteristics of patients' illnesses and outcomes, and the mechanisms of infection and disease.
"CDC is concerned about the increasing reports of community-associated MRSA. Controlling the spread of MRSA is a high priority in our efforts to prevent antimicrobial resistance. We are committed to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA